1. Scrip

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

 
• By Jessica Merrill

Express Scripts has agreed to give Praluent preferred access over Amgen's Repatha on its national formulary and is removing restrictions that have been a significant barrier to market access for the PCSK9 inhibitors.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Sanofi and Regeneron Pharmaceuticals Inc. said in March they were willing to make a deal on the cost of the PCSK9 inhibitor Praluent (alirocumab) in exchange for improved access. Now, Express Scripts Holding Co. has taken them up on the offer.

The companies announced on May 1 that Express Scripts will grant Praluent preferred access on its national formulary over Amgen Inc.'s Repatha (evolocumab) and remove some of the burdensome access restrictions in exchange for a higher rebate on the wholesale acquisition cost (WAC) of Praluent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.